Feds ac­cuse As­traZeneca of un­der­pay­ing 318 fe­male and His­pan­ic em­ploy­ees

Just a few months af­ter a fed­er­al ju­ry award­ed $2.4 mil­lion in dam­ages to a for­mer As­traZeneca sales man­ag­er who al­leged re­tal­i­a­tion for whistle­blow­ing, the phar­ma is back in hot wa­ter over the way it treats em­ploy­ees — and once again, it’s go­ing to cost the com­pa­ny.

The British phar­ma has agreed to pay $560,000 in back pay and in­ter­est to re­solve al­leged race- and gen­der-based pay dis­crim­i­na­tion af­fect­ing 318 fe­male and His­pan­ic em­ploy­ees.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.